The latest news on biomarker-guided cancer care.
Precigen to Begin Phase II Study of PRGN-2009, Keytruda in HPV-Positive Cervical Cancer
The FDA granted the firm permission to study the off-the-shelf T-cell vaccine with the immune checkpoint inhibitor in pretreated metastatic HPV-positive cervical cancer patients.
RayzeBio Advances RYZ101 to Phase III Study in SSTR-Positive Neuroendocrine Tumors
The firm will compare its investigational radiopharmaceutical to standard therapies in patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors.
In particular, Black veterans seen through an on-site program at a Philadelphia VA medical center were nearly five times more likely to get tested than through a telemedicine consult.
Yuhan Licenses HER2 Inhibitor From J INTS Bio in $325M Deal
J INTS Bio is evaluating JIN-A04 in preclinical studies as a treatment for HER2 exon 20-mutant non-small cell lung cancer.
FDA Reviewing Iovance's BLA for Melanoma TIL Therapy; Decision Expected in November
Iovance said the FDA is reviewing its BLA, and if successful, lifileucel could be the first autologous cell therapy approved for solid cancer.